Hematology/Oncology

Top Story

Top Takeaways from ASH: ELOQUENT-2 trial results of elotuzumab demonstrate immune effects

Top Takeaways from ASH: ELOQUENT-2 trial results of elotuzumab demonstrate immune effects
February 11, 2016

Updated results of the ELOQUENT-2 trial – a phase 3, randomized, open-label study – presented at the ASH Annual Meeting and Exposition focused on 3-year follow-up data. Results of the ELOQUENT-2 trial were one of several studies presented that focused on triple therapy combinations for multiple myeloma.

“Elotuzumab (Empliciti, Bristol-Myers Squibb) is a novel monoclonal antibody against this antigen known as [Signaling Lymphocytic Activation Molecule F7 (SLAMF7)],” said John Sweetenham, MD, chief medical editor of hematology for HemOnc Today and senior director of clinical affairs and executive medical director at Huntsman Cancer Institute at University of Utah. “This agent was added to other standard agents in a triple therapy combination and it produced very high response rates.”

In the Journals

Hyperthyroidism increases breast cancer risk

February 11, 2016
Women with hyperthyroidism have an increased risk for breast cancer, whereas there was a slightly decreased risk among women with hypothyroidism, according to study…
In the Journals

High ligand expression predicts panitumumab benefit for RAS wild-type colorectal cancer

February 11, 2016
High epiregulin and amphiregulin expression levels appeared to serve as a predictive biomarker for PFS benefit from panitumumab therapy in patients with RAS wild-type…
Breaking News

Doctors urge Congress to preserve the 340B Drug Pricing Program

February 11, 2016
Thousands of physicians from American safety-net hospitals signed a letter sent to Congress highlighting the importance of the 340B Drug Pricing Program.The letter asks…
In the Journals

Autologous, nonmyeloablative HSCT show promise for advanced multiple myeloma

February 11, 2016
A frontline transplant tandem approach consisting of autologous and nonmyeloablative allogeneic transplantation demonstrated promising OS and PFS among patients with…
More News Headlines »
CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Video

VIDEO: Physicians have ‘3 main opportunities’ to reduce colorectal cancer in younger patients

February 10, 2016
More »
Featured
CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan